Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension

Ronald D. Curran, Constantine Mavroudis, Carl L. Backer, Michael Sautel, Vincent R. Zales, David L. Wessel

Research output: Contribution to journalArticle

Abstract

Background.: Endothelium-derived nitric oxide (NO) is a potent vasodilator and a major mediator of pulmonary vascular tone. Methods.: Five infants underwent a trial of inhaled NO with hemodynamic monitoring in the operating room after atrioventricular canal repair. An additional 15 patients with congenital heart disease and refractory pulmonary hypertension were treated with inhaled NO for 1 day to 10 days postoperatively. Results.: In the 5 infants with atrioventricular canal, corrective surgical intervention and conventional therapy (hyperventilation, inspired oxygen fraction of 0.80, and inotropic agents) lowered mean pulmonary artery pressure from 49.5 ± 10.5 to 20.0 ± 2.2 mm Hg (p < 0.001). Adding inhaled NO further decreased mean pulmonary artery pressure to 18.0 ± 2.8 mm Hg (p = not significant). Inhaled NO had no effect on ventricular function curves (inflow occlusion) in this group. In the 15 patients with refractory postoperative pulmonary hypertension, 11 had a favorable response to inhaled NO, with a decrease in mean pulmonary artery pressure from 30.9 ± 5.8 to 23.1 ± 5.4 mm Hg (p < 0.01) in 8 patients with pulmonary artery catheters. Conclusions.: These studies demonstrate that inhaled NO has minimal beneficial effect on pulmonary artery pressure or cardiac output in infants after repair of atrioventricular canal. Inhaled NO is effective in decreasing PAP postoperatively in select patients with congenital heart disease and pulmonary hypertension refractory to conventional therapeutic modalities.

Original languageEnglish (US)
Pages (from-to)1765-1771
Number of pages7
JournalThe Annals of Thoracic Surgery
Volume60
Issue number6
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Heart Diseases
Nitric Oxide
Pulmonary Artery
Pressure
Ventricular Function
Hyperventilation
Operating Rooms
Vasodilator Agents
Cardiac Output
Blood Vessels
Catheters
Hemodynamics
Oxygen
Lung
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension. / Curran, Ronald D.; Mavroudis, Constantine; Backer, Carl L.; Sautel, Michael; Zales, Vincent R.; Wessel, David L.

In: The Annals of Thoracic Surgery, Vol. 60, No. 6, 01.01.1995, p. 1765-1771.

Research output: Contribution to journalArticle

Curran, Ronald D. ; Mavroudis, Constantine ; Backer, Carl L. ; Sautel, Michael ; Zales, Vincent R. ; Wessel, David L. / Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension. In: The Annals of Thoracic Surgery. 1995 ; Vol. 60, No. 6. pp. 1765-1771.
@article{77ca2f9b32304941a8eb826351591508,
title = "Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension",
abstract = "Background.: Endothelium-derived nitric oxide (NO) is a potent vasodilator and a major mediator of pulmonary vascular tone. Methods.: Five infants underwent a trial of inhaled NO with hemodynamic monitoring in the operating room after atrioventricular canal repair. An additional 15 patients with congenital heart disease and refractory pulmonary hypertension were treated with inhaled NO for 1 day to 10 days postoperatively. Results.: In the 5 infants with atrioventricular canal, corrective surgical intervention and conventional therapy (hyperventilation, inspired oxygen fraction of 0.80, and inotropic agents) lowered mean pulmonary artery pressure from 49.5 ± 10.5 to 20.0 ± 2.2 mm Hg (p < 0.001). Adding inhaled NO further decreased mean pulmonary artery pressure to 18.0 ± 2.8 mm Hg (p = not significant). Inhaled NO had no effect on ventricular function curves (inflow occlusion) in this group. In the 15 patients with refractory postoperative pulmonary hypertension, 11 had a favorable response to inhaled NO, with a decrease in mean pulmonary artery pressure from 30.9 ± 5.8 to 23.1 ± 5.4 mm Hg (p < 0.01) in 8 patients with pulmonary artery catheters. Conclusions.: These studies demonstrate that inhaled NO has minimal beneficial effect on pulmonary artery pressure or cardiac output in infants after repair of atrioventricular canal. Inhaled NO is effective in decreasing PAP postoperatively in select patients with congenital heart disease and pulmonary hypertension refractory to conventional therapeutic modalities.",
author = "Curran, {Ronald D.} and Constantine Mavroudis and Backer, {Carl L.} and Michael Sautel and Zales, {Vincent R.} and Wessel, {David L.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/0003-4975(95)00812-8",
language = "English (US)",
volume = "60",
pages = "1765--1771",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension

AU - Curran, Ronald D.

AU - Mavroudis, Constantine

AU - Backer, Carl L.

AU - Sautel, Michael

AU - Zales, Vincent R.

AU - Wessel, David L.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Background.: Endothelium-derived nitric oxide (NO) is a potent vasodilator and a major mediator of pulmonary vascular tone. Methods.: Five infants underwent a trial of inhaled NO with hemodynamic monitoring in the operating room after atrioventricular canal repair. An additional 15 patients with congenital heart disease and refractory pulmonary hypertension were treated with inhaled NO for 1 day to 10 days postoperatively. Results.: In the 5 infants with atrioventricular canal, corrective surgical intervention and conventional therapy (hyperventilation, inspired oxygen fraction of 0.80, and inotropic agents) lowered mean pulmonary artery pressure from 49.5 ± 10.5 to 20.0 ± 2.2 mm Hg (p < 0.001). Adding inhaled NO further decreased mean pulmonary artery pressure to 18.0 ± 2.8 mm Hg (p = not significant). Inhaled NO had no effect on ventricular function curves (inflow occlusion) in this group. In the 15 patients with refractory postoperative pulmonary hypertension, 11 had a favorable response to inhaled NO, with a decrease in mean pulmonary artery pressure from 30.9 ± 5.8 to 23.1 ± 5.4 mm Hg (p < 0.01) in 8 patients with pulmonary artery catheters. Conclusions.: These studies demonstrate that inhaled NO has minimal beneficial effect on pulmonary artery pressure or cardiac output in infants after repair of atrioventricular canal. Inhaled NO is effective in decreasing PAP postoperatively in select patients with congenital heart disease and pulmonary hypertension refractory to conventional therapeutic modalities.

AB - Background.: Endothelium-derived nitric oxide (NO) is a potent vasodilator and a major mediator of pulmonary vascular tone. Methods.: Five infants underwent a trial of inhaled NO with hemodynamic monitoring in the operating room after atrioventricular canal repair. An additional 15 patients with congenital heart disease and refractory pulmonary hypertension were treated with inhaled NO for 1 day to 10 days postoperatively. Results.: In the 5 infants with atrioventricular canal, corrective surgical intervention and conventional therapy (hyperventilation, inspired oxygen fraction of 0.80, and inotropic agents) lowered mean pulmonary artery pressure from 49.5 ± 10.5 to 20.0 ± 2.2 mm Hg (p < 0.001). Adding inhaled NO further decreased mean pulmonary artery pressure to 18.0 ± 2.8 mm Hg (p = not significant). Inhaled NO had no effect on ventricular function curves (inflow occlusion) in this group. In the 15 patients with refractory postoperative pulmonary hypertension, 11 had a favorable response to inhaled NO, with a decrease in mean pulmonary artery pressure from 30.9 ± 5.8 to 23.1 ± 5.4 mm Hg (p < 0.01) in 8 patients with pulmonary artery catheters. Conclusions.: These studies demonstrate that inhaled NO has minimal beneficial effect on pulmonary artery pressure or cardiac output in infants after repair of atrioventricular canal. Inhaled NO is effective in decreasing PAP postoperatively in select patients with congenital heart disease and pulmonary hypertension refractory to conventional therapeutic modalities.

UR - http://www.scopus.com/inward/record.url?scp=0029549531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029549531&partnerID=8YFLogxK

U2 - 10.1016/0003-4975(95)00812-8

DO - 10.1016/0003-4975(95)00812-8

M3 - Article

C2 - 8787478

AN - SCOPUS:0029549531

VL - 60

SP - 1765

EP - 1771

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -